{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Dose interruptions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Dose modifications"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Discontinuation due to AEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants according to incidence of dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Combined Safety Lead-in"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety set consisted of all participants who received at least 1 dose of study drug and had at least 1 posttreatment assessment, which may have included death. Participants were analyzed according to treatment received.","reportingStatus":"POSTED","timeFrame":"From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)","title":"(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis","type":"PRIMARY","unitOfMeasure":"Participants"}